Argenx Se: Buy Rating Backed by Vyvgart’s Robust Launch and Promising Pipeline

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Argenx Se (ARGX – Research Report), with a price target of $761.00.

Yaron Werber has given his Buy rating due to a combination of factors including the anticipated profitability of Argenx Se by 2025, driven by the robust global launch of Vyvgart for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The approval of a new prefilled syringe formulation is expected to further enhance the product’s market presence. Werber also highlights the potential success of Vyvgart in Phase 3 trials for other conditions such as myositis, thyroid eye disease (TED), and Sjogren’s syndrome, with data expected in 2026 and 2027.
Additionally, the analyst notes that Vyvgart has already established itself as a leading biologic in its field, with both intravenous and subcutaneous formulations, and has consistently surpassed sales estimates since its launch. The expected approvals of the pre-filled syringe formulation in the US, EU, and Japan by 2025 are anticipated to support further global expansion. Werber is optimistic about the future potential of Argenx’s pipeline, particularly with the promising data from ongoing studies, which could significantly increase sales beyond the conservative estimate of $7.3 billion.

In another report released on March 10, Bank of America Securities also maintained a Buy rating on the stock with a $774.00 price target.